Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$18.97Cboe Real-Time Last Sale as of 3:06PM ET 7/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.19(1.01%)
Bid (Size)$18.97 (100)
Ask (Size)$19.00 (300)
Day Low / High$18.69 - 19.04
Volume390.6 K
 

View Biotechnology IndustryPeer Comparison as of 07/17/2019

 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $18.97
Change: +0.19 (1.01%)
Volume: 390.6 K
3:06PM ET 7/17/2019
 
 

Epizyme Inc ( NASDAQ )

Price: $12.69
Change: -0.24 (1.86%)
Volume: 369.6 K
3:06PM ET 7/17/2019
 
 

Intrexon Corp ( NASDAQ )

Price: $7.57
Change: +0.21 (2.79%)
Volume: 481.9 K
3:08PM ET 7/17/2019
 
 

Rubius Therapeutics Inc ( NASDAQ )

Price: $15.07
Change: +0.26 (1.76%)
Volume: 34.0 K
3:01PM ET 7/17/2019
 
 

Esperion Therapeutics Inc ( NASDAQ )

Price: $43.71
Change: -0.53 (1.20%)
Volume: 194.4 K
3:08PM ET 7/17/2019
 

Read more news Recent News

Sector Update: Health Care Stocks Struggle This Afternoon
4:00PM ET 7/11/2019 MT Newswires

Top Health Care Stocks JNJ -0.96% PFE -2.60% ABT +0.17% MRK -4.42% AMGN -2.29% Health care stocks continued to decline on Thursday, with the NYSE...

Sector Update: Health Care
3:47PM ET 7/11/2019 MT Newswires

Health care stocks continued to decline on Thursday, with the NYSE Health Care Index dropping almost 0.3% in late trade while shares of health care...

Aimmune Therapeutics Hits Back at ICER Report on Desensitization Treatments for Peanut Allergy; Shares Fall 9%
2:03PM ET 7/11/2019 MT Newswires

Shares of Aimmune Therapeutics (AIMT) dropped 9% intraday after the firm hit back against a report on emerging desensitization treatments for peanut...

Aimmune Therapeutics Submits EU Marketing Authorization Application for Peanut Allergy Drug
7:34AM ET 6/28/2019 MT Newswires

Aimmune Therapeutics (AIMT) said it has submitted a marketing authorization application to the European Medicines Agency for AR101, an investigational...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Phone+1.650.614.5220
Number of Employees215
Recent SEC Filing06/18/20198-K
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric H. Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Senior VP-Corporate Development & StrategyMary M. Rozenman

Company Highlights

Price Open$18.78
Previous Close$18.78
52 Week Range$16.95 - 36.12
Market Capitalization$1.2 B
Shares Outstanding62.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.62
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-79.07%

Analyst Ratings as of 07/05/2019

Buy
6
Overweight
1
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset